New Cancer Gene Discovered

Key points
- Researchers at the OU Cancer Institute have identified a new gene that causes cancer.
- The gene and its protein, both called RBM3, are vital for cell division in normal cells.
- Researchers used new powerful technology to genetically “silence” the protein and reduce the level of RBM3 in cancerous cells.
- Anant said they found RBM3 protein in every stage of many cancers, and the amount of protein increased as the cancer grew.
Researchers at the OU Cancer Institute have identified a new gene that causes cancer. The ground-breaking research appears Monday in Nature’s cancer journal Oncogene.
The gene and its protein, both called RBM3, are vital for cell division in normal cells. In cancers, low oxygen levels in the tumors cause the amount of this protein to go up dramatically. This causes cancer cells to divide uncontrollably, leading to increased tumor formation.
Researchers used new powerful technology to genetically “silence” the protein and reduce the level of RBM3 in cancerous cells. The approach stopped cancer from growing and led to cell death. The new technique has been tested successfully on several types of cancers – breast, pancreas, colon, lung, ovarian and prostate.
“We are excited about this discovery because most cancers are thought to come from mutations in genes, and our studies, for the first time, have shown that too much of this type of protein actually causes normal cells to turn into cancer cells,” said Shrikant Anant, Ph.D., a cancer biologist at the OU Cancer Institute and principal investigator on the project.
Anant said they found RBM3 protein in every stage of many cancers, and the amount of protein increased as the cancer grew. The protein helped the cancer grow faster, avoid cell death and was part of the process that formed new blood vessels to feed the tumor.
“This process, called angiogenesis, is essential for tumor growth and suggests that targeting RBM3 may be an extremely powerful tool against many and perhaps all solid tumors,” Anant said.
A quarter of the funding for the cancer research comes from an $800,000 grant from the National Institutes of Health with remaining funds from the University of Oklahoma College of Medicine. The next step for Anant, Dr. Courtney Houchen and their research team at the OU Health Sciences Center is to develop agents that block the protein function in a variety of cancers. Researchers expect to start clinical trials at OU in about five years.
The University of Oklahoma Health Sciences Center
1100 N. Lindsay, Oklahoma City, OK 73104
(405) 271-4000
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsOvarian cancer: Genetic testing should be accessible to all women with the disease
The genes BRCA1 and BRCA2 play a significant role in hereditary breast and ovarian cancers. Recent media attention has focused on American actress Angelina Jolie's decision to have her ovaries and fallopian tubes…
16 April 2015
NewsNew biomarker for uterine cancer discovered
Researchers at Uppsala University have, together with researchers from Turku and Bergen, discovered a new biomarker which makes it possible to identify women with uterine cancer who have a high risk of recurrence. The…
15 April 2015
NewsResearchers discover an inactive tumor suppressor gene in lung cancer
Researchers at Genes and Cancer group at Bellvitge Biomedical Research Institute (IDIBELL), led by Montse Sanchez-Cespedes, have identified the PARD3 gene as a tumor suppressor that is inactivated in lung cancer…
15 April 2015






